News

This multi-center, randomized, double-blind study was designed to compare the efficacy, safety and tolerability of intravenous and oral Debio 1450 at two dose regimens with intravenous vancomycin /

These projects will be conducted by leading academic institutions, non-profit organizations and community groups from around the world, focusing on three key areas: translational research, efficacy studies in

This is the first application for regulatory approval of KEYTRUDA in combination with another treatment. The FDA granted Priority Review with a PDUFA, or target action, date of

L’Oreal will pay Valeant $1.3bn for three skin-care brands, CeraVe, AcneFree and AMBI. The CeraVe, AcneFree, and AMBI product lines have annualized revenue of about $168m. Founded in

In August 2016, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 18-1 to recommend approval of Arymo ER tablets for pain severe enough to require daily,

Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie. Zebra and AbbVie will

Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current

This is the second product Clinigen has licensed to Cumberland under the strategic alliance established in 2015, following the launch of Ethyol (amifostine) in the U.S. in September 2016.

The company acquired about 8.4 percent of the outstanding shares of common stock in Arrowhead Since the capital raise of May 2015, Silence has been actively evaluating a